Talvey access in Saudi Arabia: the SFDA named-patient pathway

How patients in the Kingdom of Saudi Arabia with relapsed or refractory multiple myeloma access Talvey (talquetamab-tgvs), the GPRC5D-directed bispecific antibody, when the locally available treatment ladder has been exhausted and the haematology team is sourcing US-labelled supply through the SFDA Personal Importation Program.

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

Quick orientation

Talvey (talquetamab-tgvs) is a bispecific antibody that engages G protein-coupled receptor family C group 5 member D (GPRC5D) on myeloma cells and CD3 on T cells. The US FDA granted accelerated approval on 9 August 2023 for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talvey is not registered with the Saudi Food and Drug Authority as of this review; Saudi myeloma patients access talquetamab through the SFDA Personal Importation Program corridor. Reserve Meds coordinates the US-side sourcing, the cold-chain logistics, the documentation packet the treating haematologist files, and the inpatient step-up window where the Janssen risk evaluation protocol expects monitoring.

Reserved for you.

Why patients in Saudi Arabia need Talvey via NPP

The Kingdom's tertiary haematology centres treat a substantial multiple myeloma volume, particularly at King Faisal Specialist Hospital and Research Centre in Riyadh, Jeddah, and Madinah, the King Abdulaziz Medical City and Ministry of National Guard Health Affairs network, King Saud University Medical City, and the major private networks Dr. Sulaiman Al Habib Medical Group, Dr. Soliman Fakeeh Hospital, Saudi German Hospital, and Dallah Hospital. Saudi myeloma patients reach the GPRC5D bispecific conversation in three converging patterns. First, post-CAR-T relapse. A patient who has had cilta-cel or ide-cel through an international referral and progressed needs an off-the-shelf option that targets a different antigen; talquetamab targets GPRC5D, a distinct mechanism from the BCMA family. Second, BCMA-bispecific failure or intolerance. Teclistamab (Tecvayli) and elranatamab (Elrexfio) target BCMA; a patient who progressed on or could not tolerate either has talquetamab as the next bispecific option with a different antigen target and a different adverse event profile. Third, fifth-line-or-later relapse where the standard lines (bortezomib, lenalidomide, daratumumab, carfilzomib, pomalidomide, isatuximab, selinexor) have been exhausted and CAR-T is not accessible in the timeline disease progression allows.

In each of those three patterns, the patient meets the FDA-approved indication and the locally available alternatives are either not registered (CAR-T, the other bispecifics) or have already failed. The SFDA Personal Importation Program is the lawful corridor through which a SCFHS-licensed haematologist can direct US-labelled talquetamab to a specific named patient in the Kingdom.

The SFDA Personal Importation Program for Talvey

The SFDA Personal Importation Program allows a Saudi Commission for Health Specialties (SCFHS) licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority (US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally available alternative is not suitable. Talvey qualifies under the reference-authority test cleanly: FDA accelerated approval 9 August 2023 (BLA 761342) and EMA conditional marketing authorisation 22 August 2023. The clinical-equivalence test is met in each of the three NPP-driving patterns; talquetamab is the only GPRC5D-directed bispecific antibody approved in any reference jurisdiction, with no clinically equivalent locally available option.

The clinical-justification angle in a Talvey SFDA PIP file typically anchors on one of two patterns. For a post-CAR-T or post-BCMA-bispecific relapse case, the haematologist documents the prior BCMA-directed therapy, the duration of response, the time to progression, the current disease status, and the rationale for switching to GPRC5D-directed bispecific antibody therapy. For a fifth-line-or-later relapse case without prior CAR-T or BCMA-bispecific exposure, the haematologist documents the four prior lines (proteasome inhibitor, immunomodulatory agent, anti-CD38 antibody, and one additional class member) with response and duration, the current disease status, and the rationale for talquetamab specifically.

A complete application includes the clinical justification letter on institutional letterhead from the treating haematologist, the physician's active SCFHS license in haematology or medical oncology, an anonymised patient identifier, full product details (brand Talvey, generic talquetamab-tgvs, manufacturer Janssen Biotech, strength 3 mg/1.5 mL or 40 mg/1.0 mL single-dose vials, lot, expiry, requested quantity for the planned step-up plus initial maintenance window), the destination dispensing facility SFDA license, the haematology service line confirmation, and a chain-of-custody plan documenting validated cold-chain transit with the 24 to 48 hour room-temperature excursion budget noted per the Janssen storage label.

Routine cases run 10 to 21 business days through SFDA review. Complex cases or first-import requests extend to 6 to 10 weeks. SFDA retains discretion on timing and we do not promise specific durations.

Where Talvey gets dispensed in Saudi Arabia

Talvey requires subcutaneous administration with a step-up dosing schedule that mandates inpatient or close-observation monitoring during the first two or three doses for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome surveillance. The dispensing facility list in the Kingdom narrows from the full Saudi specialty hospital network to those institutions with validated 2 to 8 degree Celsius pharmacy storage, an inpatient haematology service line with CRS and ICANS management protocols including tocilizumab availability, and physicians experienced with the bispecific antibody step-up workflow. The qualifying centres include King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh, Jeddah, and Madinah, which holds the most established myeloma and stem cell transplant programme in the Kingdom and has run the relevant Janssen and BMS clinical trials at multiple sites; King Abdulaziz Medical City and the Ministry of National Guard Health Affairs network in Riyadh and Jeddah; King Saud University Medical City; and the private network institutions Dr. Sulaiman Al Habib Medical Group, Dr. Soliman Fakeeh Hospital, Saudi German Hospital, and Dallah Hospital with established haematology-oncology service lines.

The step-up dosing schedule for the weekly regimen consists of step-up dose 1 of 0.01 mg/kg subcutaneously, step-up dose 2 of 0.06 mg/kg subcutaneously 2 to 4 days later, and the first treatment dose of 0.4 mg/kg subcutaneously 2 to 4 days after that, followed by 0.4 mg/kg weekly thereafter. The biweekly regimen uses three step-up doses (0.01, 0.06, 0.32 mg/kg) before the first treatment dose of 0.8 mg/kg every two weeks. Each step-up dose and the first treatment dose require 48-hour inpatient or close-observation monitoring per Janssen protocol because cytokine release syndrome (incidence approximately 76 percent in MonumenTAL-1, predominantly grade 1 or 2) and neurotoxicity (approximately 10 to 14 percent) cluster in the early-cycle window.

For patients outside the major centres, the standard route is an SFDA-licensed specialty importer in Riyadh or Jeddah filing the PIP application and coordinating delivery under chain-of-custody documentation to the referring physician's hospital. The step-up admission is then scheduled at the referring centre or, where the local capability is not present, the patient travels to a major Riyadh or Jeddah centre for the inpatient step-up window before returning to local outpatient maintenance.

Real cost picture for Talvey in Saudi Arabia

US wholesale acquisition cost for Talvey is approximately USD 25,000 per month at the maintenance dosing for an average-weight adult, per Janssen published pricing. Per-vial pricing on the 40 mg/1.0 mL vial sits at approximately USD 7,950 per vial and the 3 mg/1.5 mL vial at approximately USD 596 per vial, with monthly cost driven by the weekly versus biweekly schedule, the patient's weight, and the number of doses per month. The Saudi riyal is pegged to the US dollar at approximately 3.75 SAR to 1 USD, so a maintenance month at US WAC equivalents converts to approximately SAR 94,000. The step-up window carries lower drug cost because step-up doses are subtherapeutic; cumulative cost concentrates in the maintenance phase.

The all-in delivered-to-Kingdom cost typically includes US drug acquisition, cold-chain international logistics in the SAR 1,500 to 5,600 (USD 400 to 1,500) range per shipment, SFDA regulatory documentation handling, customs clearance, and the Reserve Meds coordination fee. The inpatient step-up monitoring fees at the dispensing Saudi hospital are billed by that hospital and are not part of the Reserve Meds quote. Reserve Meds quotes an indicative range at intake and a firm itemised quote after documentation review.

On the insurer side, Bupa Arabia, Tawuniya, and MedGulf Arabia each handle myeloma bispecific named-patient imports case by case under CCHI plan-structure rules and typically with prior authorisation and significant patient coinsurance. We supply the documentation that lets the insurer assess; the claim itself sits with you or your hospital. Cash-pay is the default operating posture; reimbursement is sought after delivery where the plan permits.

Typical timeline for Talvey in Saudi Arabia

From waitlist submission to first step-up dose, the typical Talvey case in Saudi Arabia runs as follows. Reserve Meds confirms eligibility within 24 to 48 hours and sends a documentation kit to the treating haematologist. The physician or hospital import pharmacy or SFDA-licensed importer files the PIP application, which clears in 10 to 21 business days for routine cases. In parallel, Reserve Meds aligns US-side specialty pharmacy sourcing, validated cold-chain qualification, and the shipment plan with the 24 to 48 hour room-temperature excursion budget noted in the chain-of-custody plan. Once SFDA approval is issued, US release and shipment add 5 to 10 business days for cold-chain transit plus customs clearance into the importer's bonded warehouse or directly to the hospital. The step-up admission is scheduled at the dispensing hospital, typically a 5 to 7 day inpatient window for the step-up doses and the first treatment dose. The full cycle from waitlist to first treatment dose is typically 4 to 6 weeks. Re-supply on the weekly or biweekly cadence is then planned in 8 to 12 week shipment windows.

What your physician needs to provide

The clinical justification letter is the cornerstone of the SFDA PIP package for Talvey. On institutional letterhead, signed by a SCFHS-licensed haematologist or medical oncologist, the letter typically documents the multiple myeloma diagnosis with ISS or R-ISS staging and baseline cytogenetics, the prior treatment history (regimen, duration, best response, reason for discontinuation for each line), the current disease status with M-protein, light-chain, bone marrow plasma cell percentage, and imaging summary, the rationale for GPRC5D-directed therapy specifically rather than BCMA-directed bispecific or CAR-T, the proposed step-up and maintenance schedule (weekly 0.4 mg/kg or biweekly 0.8 mg/kg after step-up), and the monitoring plan covering cytokine release syndrome and neurotoxicity with tocilizumab and supportive care protocols available at the dispensing facility.

The letter also addresses the GPRC5D-class-specific adverse events: dysgeusia (approximately 72 percent of patients, generally grade 1 or 2 but persistent), nail toxicity (approximately 56 percent), skin disorders including rash and xerosis (approximately 67 percent), and weight decrease (approximately 41 percent). The monitoring plan should describe the nutrition support pathway, the dental and ENT input where dysgeusia is severe, and the dermatology and podiatry consults that often accompany the GPRC5D adverse event cluster. Infectious disease screening follows the broader bispecific class profile: hepatitis B screening at baseline with antiviral prophylaxis where indicated, CMV monitoring during therapy, and IVIG support if hypogammaglobulinaemia develops. The physician confirms their SCFHS license is active for the requested treatment window and the dispensing facility has the inpatient monitoring capability for the step-up window.

Common questions about Talvey in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover Talvey?

Each insurer assesses bispecific named-patient imports case by case under CCHI plan-structure rules with prior authorisation and typically with significant patient coinsurance. Reserve Meds supplies the documentation; the claim itself sits with you or your hospital. Cash-pay is the default operating posture.

Will my SCFHS-licensed haematologist's letter be sufficient?

Yes. SCFHS-licensed haematologists, medical oncologists, and transplant physicians at KFSH&RC, KAMC, MNGHA, KSUMC, and the major private networks have full signing authority on PIP applications for Talvey. The dispensing facility must have the inpatient monitoring capability for the step-up window, which is confirmed in the application.

How does Talvey compare to Tecvayli or Elrexfio?

Tecvayli (teclistamab) and Elrexfio (elranatamab) are BCMA-directed bispecifics; Talvey is the GPRC5D-directed bispecific. Mechanism-of-action diversification matters when a patient has progressed on BCMA-directed therapy. The GPRC5D class shows distinct adverse event signatures, particularly dysgeusia, nail and skin toxicity, and weight loss, which are largely absent from the BCMA class. The choice between bispecifics is a haematology team decision based on prior therapy, current disease, and patient tolerance considerations. See our dedicated pages on Tecvayli in Saudi Arabia and Carvykti in Saudi Arabia.

What about the dysgeusia and skin and nail adverse events?

The GPRC5D target is expressed on tongue keratinocytes, hair follicles, nail beds, and skin in addition to malignant plasma cells. Dysgeusia, nail dystrophy, hair changes, and rash are the on-target consequences. These are largely grade 1 or 2 but can be persistent and clinically meaningful for quality of life. The nutrition support team and dermatology consult become important parts of the care plan; dose interruption or schedule modification to biweekly dosing may improve tolerance.

Can Talvey be self-administered at home after step-up?

The maintenance subcutaneous doses can be administered in an outpatient infusion suite or, in some centres after several maintenance doses without CRS or ICANS events, at home with appropriate training and a caregiver present. The first treatment dose and step-up doses are inpatient or close-observation per Janssen protocol. The dispensing Saudi hospital determines the transition point on a patient-by-patient basis.

What about hepatitis B reactivation?

Bispecific antibody therapy in myeloma carries hepatitis B reactivation risk; the Janssen prescribing information requires hepatitis B screening at baseline and antiviral prophylaxis where indicated. The treating SCFHS-licensed physician documents screening at baseline and prescribes prophylaxis per current guidelines.

What is the duration of therapy?

Talvey is administered until disease progression or unacceptable toxicity. The MonumenTAL-1 median duration of response was approximately 9 to 12 months in the BCMA-naive cohort. Some centres consider dose holidays or schedule de-intensification after a sustained response, particularly when dysgeusia or skin adverse events affect quality of life; the Janssen prescribing information does not formally support fixed-duration therapy.

Where Reserve Meds fits in Talvey cases

Reserve Meds is a US-based concierge coordinator. We do not replace the treating haematologist, do not replace SFDA, and do not replace the Saudi dispensing pharmacy. What we do for a Saudi Talvey case is orchestrate US-side specialty pharmacy sourcing through a DSCSA-compliant channel, prepare the regulatory documentation kit the treating haematologist needs (with the GPRC5D-specific adverse event monitoring guidance surfaced in the patient-facing case summary), coordinate cold-chain international logistics with continuous temperature monitoring and the 24 to 48 hour room-temperature excursion budget noted, and assign a single named coordinator through the step-up admission, the maintenance shipment cadence, and the continuity-of-supply window. Bispecific antibody coordination is a defining concierge case for Reserve Meds because the step-up monitoring, the maintenance shipment cadence, and the supportive care framework all sit at the intersection of US sourcing, Saudi regulatory documentation, and dispensing-facility logistics. No prior Reserve Meds dispensed-case experience as of this page; standard NPP coordination under our cold-chain biologic and step-up bispecific playbook applies.

Next step

If the haematologist has prescribed Talvey and the family is weighing the cross-border named-patient route, the waitlist is the first step. We confirm eligibility within 24 to 48 hours and send the documentation kit to the treating physician.

Add my Saudi Arabia Talvey case to the waitlist